- May 19, 2023BrainStorm Cell Therapeutics Summarizes Key Messages from Its Participation as Expert Speakers in an Invited Presentation and Panel Discussion at The 2023 ALS Drug Development Summit
- Presentation by Co-CEO Stacy Lindborg, Ph.D., held at 2023 ALS Drug Development Summit - Summit Focused On Transforming Translational Tools to Accelerate Future ALS Approvals NEW YORK, May 19,...
- May 15, 2023BrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
Biologics License Application for NurOwn® for the treatment of ALS to be subject of an upcoming FDA Advisory Committee Meeting Conference call and webcast at 8:00 a.m. Eastern Time today NEW...
- May 9, 2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update...
- Apr 24, 2023BrainStorm Cell Therapeutics Strengthens Leadership Team with Appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical Officer
Dr. Taylor has extensive biopharma industry expertise in neurodegenerative disease and experience leading drug launches and post-approval studies Company begins a targeted capability build to...
- Mar 30, 2023BrainStorm Cell Therapeutics Announces Full Year 2022 Financial Results and Provides a Corporate Update
Biologics License Application for NurOwn® for the treatment of ALS to be discussed in an upcoming FDA Advisory Committee Meeting Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK,